Osteointegration of dental implants in menopausal osteoporosis: optimization strategies, ways and prospects of solving the problem

DOI: https://doi.org/10.29296/25877305-2023-07-18
Issue: 
7
Year: 
2023

G. Brudyan(1); M. Khabibulina(2), Candidate of Medical Sciences; Professor
V. Strukov(3), MD; M. Sergeeva-Kondrachenko(3), MD; O. Vinogradova(3), MD;
A. Denisova(3), MD; Professor I. Moiseeva(4), MD; Associate Professor E. Petrova(4), Candidate of Medical Sciences; Associate Professor P. Poluboyarinov(4), Candidate of Agricultural Sciences; D. Vikhrev(3), Candidate of Medical Sciences; E. Panina(4), Candidate of Medical Sciences; A. Fedorov(5); S. Burmistrova(6)
1-Voskresensk Dental Polyclinic
2-Ural State Medical University, Ministry of Health of Russia, Yekaterinburg
3-Penza Institute for Postgraduate Training of Physicians, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
4-Penza State University
5-Penza State Agrarian University
6-Acad. I.P. Pavlov Ryazan State Medical University

The influence of climacteric osteoporosis on the process of osseointegration of dental implants is considered. Particular attention is paid to the relationship between menopause, osteoporosis and the success of osseointegration. In this regard, strategies for optimizing osseointegration are discussed, including the use of drugs to increase bone density and leveling of menopause symptoms in the period of preparation for implantation, the use of agents to improve the quality of osseointegration during and after implantation. Prospects and directions for further research in this area are determined.
Keywords: 
osteointegration
dental implants
menopause
osteoporosis
bone density
hormone therapy
Femoklim
Osteomed Forte.

References: 
  1. Хабибулина М.М. Кардиоваскулярный риск при эстрогенодефиците в доклимактрических периодах. Монография. 2014; 193 [Khabibulina M.M. Cardiovascular risk in estrogen deficiency in premenopausal periods. Monograph. 2014;193 (in Russ.)].
  2. Дедов И.И., Мельниченко Г.А., Белая Ж.Е. и др. Остеопороз – от редкого симптома эндокринных болезней до безмолвной эпидемии XX–XXI века. Проблемы эндокринологии. 2011; 57 (1): 35–45 [Dedov I.I., Melnichenko G.A., Belaya Zh.E. et al. Osteoporosis – from a rare symptom of endocrine diseases to a silent epidemic of the XX–XXI century. Problemy endokrinologii. 2011; 57 (1): 35–45 (in Russ.)]. DOI: 10.14341/probl201157135-45
  3. Xu S.Y., Shi P., Zhou R.M. Post-menopausal oestrogen deficiency induces osteoblast apoptosis via regulating HOTAIR/miRNA-138 signalling and suppressing TIMP1 expression. J Cell Mol Med. 2021; 25 (10): 4572–82. DOI: 10.1111/jcmm.16216
  4. Bellido T., Jilka R. L, Boyce B.P. et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995; 95 (6): 2886–95. DOI: 10.1172/JCI117995
  5. Hreinsson J.G., Otala M., Fridstrom M. et al. Follicles Are Found in the Ovaries of Adolescent Girls with Turner’s Syndrome. J Clin Endocrinol Metab. 2002; 87 (8): 3618–23. DOI: 10.1210/jcem.87.8.8753
  6. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21 (2): 115–37. DOI: 10.1210/edrv.21.2.0395
  7. Chen J.R., Kousteni S., Bellido T. et al. Gender-independent induction of murine osteoclast apoptosis in vitro by either estrogens or non-aromatizable androgens. J Bone Miner Res. 2001; 16 (1): 159.
  8. Kasperk C.H., Wergedal J.E., Farley J.R. et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology. 1989; 124 (3): 1576–8. DOI: 10.1210/endo-124-3-1576
  9. Vanderschueren D., Laurent M.R., Claessens F. et al. Sex steroid actions in male bone. Endocr Rev. 2014; 35 (6): 906–60. DOI: 10.1210/er.2014-1024
  10. Muñoz-Torres M., Jódar E., Quesada M. et al. Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy. Calcif Tissue Int. 1995; 57 (2): 94–6. DOI: 10.1007/BF00298426
  11. Misakian A., McLoughlin M., Pyle L.C. et al. Case Report: Low Bone and Normal Lean Mass in Adolescents With Complete Androgen Insensitivity Syndrome. Front Endocrinol. 2021; 12: 727131. DOI:10.3389/fendo.2021.727131
  12. Кузнецова И.В., Чилова Р.А. Менопаузальный остеопороз в практике врача-гинеколога. Медицинский совет. 2021; 12: 320–31 [Kuznetsova I.V., Chilova R.A. Menopausal osteoporosis in the practice of a gynecologist. Medical Council. 2021; 12: 320–31 (in Russ.)]. DOI: 10.21518/2079-701X-2021-12-320-331
  13. Panay N., Hamoda H., Arya R. et al. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause International. 2013; 19 (2): 59–68. DOI: 10.1177/1754045313489645
  14. Патент на изобретение РФ №2648470. Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде. Выдан 26.03.2018 [Patent of the Russian Federation No.2648470. A method for optimizing the treatment of women with cardiotropic therapy and hormone replacement therapy for estrogen deficiency with arterial hypertension in the late reproductive period. Issued on 03/26/2018 (in Russ.)].
  15. Deli T., Orosz M., Jakab A. Hormone Replacement Therapy in Cancer Survivors – Review of the Literature. Pathol Oncol Res. 2020; 26: 63–78. DOI: 10.1007/s12253-018-00569-x
  16. Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016; 106 (7): 1588–99. DOI: 10.1016/j.fertnstert.2016.09.046
  17. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone. 2010; 47: 169–80. DOI: 10.1016/j.bone.2010.05.019
  18. Leung F., Lau T-W., To M., et al. Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2009; 2009: bcr10.2008.1073. DOI: 10.1136/bcr.10.2008.1073.
  19. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63: 1567–75. DOI: 10.1016/j.joms.2005.07.010
  20. Farrugia M.C., Summerlin D.J., Krowiak E. et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope. 2006; 116: 115–20. DOI: 10.1097/01.mlg.0000187398.51857.3c
  21. Chen Y.M., Chen D.Y., Chen L.K. et al. Alendronate and risk of esophageal cancer: a nationwide population-based study in Taiwan. J Am Geriatr Soc. 2011; 59: 2379–81. DOI: 10.1111/j.1532-5415.2011.03693.x
  22. Haber S.L., McNatty D. An evaluation of the use of oral bisphosphonates and risk of esophageal cancer. Ann Pharmacother. 2012; 46: 419–23. DOI: 10.1345/aph.1Q482
  23. Хабибулина М.М. Влияние альтернативного варианта заместительной гормональной терапии на кардиальные проявления при метаболически здоровом ожирении и гипоэстрогенемии. Фармация. 2022; 71 (4): 46–51 [Khabibulina M.M. Effect of alternative hormone replacement therapy on cardiac manifestations in metabolically healthy obesity and hypoestrogenemia. Farmaciya. 2022; 71 (4): 46–51 (in Russ.)]. DOI: 10.29296/25419218-2022-04-07
  24. Хабибулина М.М., Шамилов М.Д. Влияние препарата «Фемо-Клим» на психовегетативный статус, кардиалгию у женщин с метаболически здоровым ожирением и эстрогенодефицитом в пременопаузе. Врач. 2022; 33 (4): 64–8 [Khabibulina M., Shamilov M. Effect of Femo-Klim on psychoautonomic status, episodes of cardialgia in premenopausal women with metabolically healthy obesity and estrogen deficiency Vrach. 2022; 33 (4): 64–8 (in Russ.)]. DOI: 10.29296/25877305-2022-04-09
  25. Хабибулина М.М., Шамилов М.Д. Фитоэстрогены («Фемо-Клим») и психологическое состояние при гипоэстрогении и абдоминальном ожирении. Акушерство и гинекология: Новости. Мнения. Обучение. 2022; 10 (3): 107–12 [Khabibulina M.M., Shamilov M.D. Phytoestrogens ("Femo-Klim") and psychological state in women with hypoestrogenism and abdominal obesity. Obstetrics and Gynecology: News, Opinions, Training. 2022; 10 (3): 107–12 (in Russ.)]. DOI: 10.33029/2303-9698-2022-10-3-107-112
  26. Хабибулина М.М., Шамилов М.Д. Влияние препарата «Фемо-Клим» на качество жизни молодых женщин с измененным гормональным фоном. Врач. 2022; 33 (3): 12–6 [Khabibulina M., Shamilov M. Effect of Femo-Klim on quality of life in young women with hormonal changes. Vrach. 2022; 33 (3): 12–6 (in Russ.)]. DOI: 10.29296/25877305-2022-03-02
  27. Потупчик Т. Возможности применения препарата Фемо-Клим в климактерическом периоде. Врач. 2019; 30 (8): 80–5 [Potupchik T. Possibilities of using Femo-Klim in the menopausal period. Vrach. 2019; 30 (8): 80–5 (in Russ.)]. DOI: 10.29296/25877305-2019-08-17
  28. Santosh P., Nidhi S., Sumita K., et al. Oral findings in postmenopausal women attending dental hospital in Western part of India. J Clin Exp Dent. 2015; 5 (1): 8–12. DOI: 10.4317/jced.50928
  29. Орехова Л.Ю. Заболевания пародонта. Поли Медиа Пресс, 2004; с. 195–9 [Orekhova L.Yu. Periodontal diseases. Poly Media Press, 2004; р. 195–9 (in Russ.)].
  30. Rook G.A.W., Hernandez-Pando R., Lightman S.L. Hormones, peripherally activated prohormones and regulation of the Thl/Th2 balance. Immunol Today. 1994; 15: 301–3. DOI: 10.1016/0167-5699(94)90075-2
  31. Jilka R.L., Hangok G., Girasole G. et al. Increased osteoclast developmentafter estrogen loss: mediation by interleukin-6. Science. 1992; 257: 88–91. DOI: 10.1126/science.1621100
  32. Mattson J.S., Cerutis D.R., Parrish L.C. Osteoporosis: a review and its dental implications. Compend Contin Educ Dent. 2002; 23 (II): 1001–4.
  33. Дорофеев А.Е., Пустохина И.Г., Енина Ю.И. Изменения в полости рта у женщин в период менопаузы. Здоровье и образование в XXI веке. 2019; 21 (6): 18–21 [Dorofeev A.E., Pustokhina I.G., Enina Yu.I. Changes in the oral cavity in women during menopause. Health and Education Millennium. 2019; 21 (6): 18–21 (in Russ.)]. DOI: 10.26787/nydha-2226-7425-2019-21-6-18-21
  34. Ko Y.-C., Tsai M.-T., Fuh L.-J. et al. Association between Age of Menopause and Thickness of Crestal Cortical Bone at Dental Implant Site: A Cross-Sectional Observational Study. Int J Environ Res Public Health. 2020; 17 (16): 58–68. DOI: 10.3390/ijerph17165868
  35. Походенько-Чудакова И.О., Карсюк Ю.В. Обоснование исследования по разработке системы прогнозирования исходов дентальной имплантации. Аналитический обзор литературы. Вестник ВГМУ. 2014; 13 (1): 6–12 [Pokhodenko-Chudakova I.O., Karsyuk Yu.V. Substantiation of the study on the development of a system for predicting the outcomes of dental implantation. Analytical review of literature. Vestnik VGMU. 2014; 13 (1): 6–12 (in Russ.)].
  36. Pogrel M.A., Ruggiero S.L. Previously successful dental implants can fail when patients commence anti-resorptive therapy-a case. Int J Oral Maxillofac Surg. 2018; 47 (2): 220–2. DOI: 10.1016/j.ijom.2017.07.012
  37. Memon S., Weltman R.L., Katancik J.A. Oral Bisphosphonates: Early Endosseous Dental Implant Success and Crestal Bone. A Retrospective Study. Int J Oral Maxillofac Implants. 2012; 279 (5): 1216–22.
  38. Ishii J. H. Osteoporose e os Implantes Dentários. São Paulo, 2009; 24 p.
  39. Basso F., Pansani T.N., Soares D.G., et al. Influence bisphosphonates on the adherence and metabolism of epithelial cells and gingi fibroblasts to titanium. Clin Oral Investig. 2018; 22 (2): 893–900. DOI: 10.1007/s00784-017-2167-2
  40. Струков В.И., Елистратов Д.Г., Вихрев Д.В. и др. Персонифицированный подход к диагностике и терапии коморбидного остеопороза в клинической практике. Врач. 2022; 33 (6): 20–5 [Strukov V., Elistratov D., Vikhrev D. et al. A personalized approach to therapy for comorbid osteoporosis in clinical practice. Vrach. 2022; 33 (6): 20–5 (in Russ.)]. DOI: 10.29296/25877305-2022-06-03
  41. Бурмистрова Л.А. Физико-химический анализ и биохимическая оценка биологической активности трутневого расплода. Дис. … канд. биол. наук. Рыбное, 1999 [Burmistrova L.A. Physico-chemical analysis and biochemical evaluation of the biological activity of drone brood. Dis. … cand. biol. nauk. Rybnoe, 1999 (in Russ.)].
  42. Митрофанов Д.В., Будникова Н.В., Брандорф А.З. Применение трутневого расплода в рациональном питании и апитерапии. Аграрная наука Евро-Северо-Востока. 2021; 22 (2): 188–203 [Mitrofanov D.V., Budnikova N.V., Brandorf A.Z. Application of drone brood in rational nutrition and apitherapy. Agricultural Science Euro-North-East. 2021; 22 (2): 188–203 (in Russ.)]. DOI: 10.30766/2072-9081.2021.22.2.188-203
  43. Lazaryan D.S. Comparative amino acids analysis in bee brood. Pharmaceutical Chemistry Journal. 2002; 36: 680–2. DOI:10.1023/A:1023469931357
  44. Viguet-Carrin S., Garnero P., Delmas P. D. D. The role of collagen in bone strength. Osteoporosis Int. 2006; 17 (3): 319–36. DOI: 10.1007/s00198-005-2035-9
  45. Reinwald S., Weaver C.M., Kester J. The Health Benefits of Calcium Citrate Malate: A Review of the Supporting Science. Adv Food Nutr Res. 2008; 54: 219–346. DOI: 10.1016/S1043-4526(07)00006-X
  46. Чекман И.С. Кальция цитрат – клинико-фармакологическая активность. Провизор. 2003; 11 [Chekman I.S. Calcium citrate - clinical and pharmacological activity. Provizor. 2003; 11 (in Russ.)].
  47. Зорян Е.В., Зорян А.В. Конституциональные особенности пациентов и их роль в прогнозировании и профилактике стоматологических заболеваний. Стоматолог. 2008; 1 [Zoryan E.V., Zoryan A.V. Constitutional features of patients and their role in the prediction and prevention of dental diseases. Stomatolog. 2008; 1 (in Russ.)]. URL: https://provisor.com.ua/100matolog/archive/2008/1/constitution.php
  48. Дьячкова Е.Ю., Трифонова Д.О., Ибадулаева М.О. и др. Влияние дефицита витамина D на состояние зубочелюстной системы: обзорная статья. Остеопороз и остеопатии. 2021; 24 (1): 19–25 [Diachkova E.Y., Trifonova D.O., Ibadulaeva M.O. et al. Vitamin D imbalance effects on dentoalveolar system: a review. Osteoporosis and Bone Diseases. 2021; 24 (1): 19–25 (in Russ.)]. DOI: 10.14341/osteo12719
  49. Макацария А.Д., Дикке Г.Б. Влияние дефицита магния на течение климактерического синдрома. Акушерство и гинекология. 2017; 6: 118–26 [Makatsariya A.D., Dikke G.B. Impact of magnesium deficiency on the course of climacteric syndrome. Obstetrics and Gynecology. 2017; 6: 118–26 (in Russ.)]. DOI: 10.18565/aig.2017.6.118-26
  50. Громова О.А., Торшин И.Ю., Лиманова О.А. Кальций и его синергисты в поддержке структуры соединительной и костной ткани. Лечащий врач. 2014; 5: 69–76 [Gromova O.A., Torshin I.Yu., Limanova O.A. Calcium and its synergists in supporting the structure of connective and bone tissue. Lechashchij vrach. 2014; 5: 69–76 (in Russ.)].
  51. Спиричев В.Б. Витамины и минеральные вещества в комплексной профилактике и лечении остеопороза. Вопросы питания. 2003; 1: 34–43 [Spirichev V.B. Vitamins and minerals in the complex prevention and treatment of osteoporosis. Voprosy pitaniya. 2003; 1: 34–43(in Russ.)].
  52. Исмаилова О., Еремина Н., Струков В. и др. Клинико-патогенетические особенности хронического генерализованного пародонтита у женщин в менопаузе и его морфометрические проявления на фоне комплексной терапии с применением препарата Остеомед Форте. Врач. 2019; 30 (10): 40–3 [Ismailova O., Eremina N., Strukov V. et al. Clinical and pathogenetic features of chronic generalized periodontitis in menopausal women and its morphometric manifestations during combination therapy using Osteomed Forte. Vrach. 2019; 30 (10): 40–3 (in Russ.)]. DOI: 10.29296/25877305-2019-10-08